Essa Pharma (NASDAQ:EPIX; TSX:EPI) has appointed Peter Virsik as executive vice-president and chief operating officer.
Mr. Virsik will be responsible for leading Essa’s overall business development and corporate strategy as the company further advances a clinical development plan for its novel prostate cancer therapeutic, EPI-506.
Mr. Virsik is a seasoned biopharmaceutical executive with over 20 years experience in corporate development, new product planning, licensing and alliance management with global pharmaceutical organizations.
Prior to joining Essa, he served as SVP, corporate development, for XenoPort, which was acquired by Arbor Pharmaceuticals, leading licensing, strategy, new product planning and alliance management. During his tenure at XenoPort, he played an integral role in the licensing and commercialization of Horizant.
“We believe that the successful development of Essa’s innovative therapeutics can dramatically improve the lives of patients with metastatic prostate cancer,” president and CEO, David Parkinson, said in a statement. “Peter’s expertise and experience will be invaluable as we continue to build Essa and advance our first product towards that goal.”